Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are two stocks likely to meet or exceed Wall Street’s lofty expectations and one where consensus estimates seem disconnected from reality.
One Stock to Sell:
ANI Pharmaceuticals (ANIP)
Consensus Price Target: $110.63 (47.8% implied return)
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Does ANIP Give Us Pause?
- Smaller revenue base of $883.4 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Expenses have increased as a percentage of revenue over the last two years as its adjusted operating margin fell by 1.6 percentage points
- Negative returns on capital show that some of its growth strategies have backfired
ANI Pharmaceuticals is trading at $74.87 per share, or 8.2x forward P/E. If you’re considering ANIP for your portfolio, see our FREE research report to learn more.
Two Stocks to Watch:
Analog Devices (ADI)
Consensus Price Target: $384.53 (23.6% implied return)
Founded by two MIT graduates, Ray Stata and Matthew Lorber in 1965, Analog Devices (NASDAQ: ADI) is one of the largest providers of high performance analog integrated circuits used mainly in industrial end markets, along with communications, autos, and consumer devices.
Why Does ADI Stand Out?
- Market share has increased this cycle as its 14.9% annual revenue growth over the last five years was exceptional
- Offerings are difficult to replicate at scale and lead to a premier gross margin of 60.3%
- Strong free cash flow margin of 36.7% enables it to reinvest or return capital consistently, and its recently improved profitability means it has even more resources to invest or distribute
Analog Devices’s stock price of $311.22 implies a valuation ratio of 25.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Mirion (MIR)
Consensus Price Target: $28.80 (45.2% implied return)
With its technology protecting workers in over 130 countries and equipment used in 80% of cancer centers worldwide, Mirion Technologies (NYSE: MIR) provides radiation detection, measurement, and monitoring solutions for medical, nuclear energy, defense, and scientific research applications.
Why Does MIR Catch Our Eye?
- Impressive 11.8% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Operating margin improvement of 10.4 percentage points over the last five years demonstrates its ability to scale efficiently
- Free cash flow margin increased by 11.1 percentage points over the last five years, giving the company more capital to invest or return to shareholders
At $19.83 per share, Mirion trades at 35.6x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
